Selective Targeting of Dopamine Receptor Subtypes by Antipsychotic Agents: The Relationship Between Pharmacodynamic Properties and Therapeutic Efficacy
DOI:
https://doi.org/10.31149/ijimm.v4i5.2892Keywords:
Dopamine Receptor Subtypes, Antipsychotic Drugs, Pharmacodynamics, D2 Receptor Occupancy, Selective Receptor Targeting, Partial Agonism, Extrapyramidal Side Effects, Therapeutic Efficacy, Dopaminergic Neurotransmission, Atypical Antipsychotics, Receptor Binding Affinity, Personalized PsychiatryAbstract
Antipsychotic medications exert their therapeutic effects primarily through modulation of dopaminergic neurotransmission; however, increasing evidence indicates that selective interactions with distinct dopamine receptor subtypes play a critical role in determining both clinical efficacy and tolerability. This study explores the relationship between subtype-selective dopaminergic activity of antipsychotic agents and their pharmacodynamic profiles, with particular emphasis on D1-, D2-, D3-, and D4-receptor interactions. A qualitative analytical approach was employed, synthesizing data from contemporary pharmacological and clinical literature to evaluate how receptor binding affinity, intrinsic activity (antagonism vs. partial agonism), and receptor occupancy thresholds influence therapeutic outcomes. Special attention was given to differences between first-generation and second-generation antipsychotics, as well as newer agents exhibiting functional selectivity.
References
[1] S. Kapur and D. Mamo, “Half a century of antipsychotics and still a central role for dopamine D2 receptors,” Progress in Neuro-Psychopharmacology and Biological Psychiatry, vol. 27, no. 7, pp. 1081–1090, 2003.
[2] P. Seeman, “Dopamine D2 receptors as treatment targets in schizophrenia,” Clinical Schizophrenia & Related Psychoses, vol. 4, no. 1, pp. 56–73, 2010.
[3] H. Y. Meltzer, “Update on typical and atypical antipsychotic drugs,” Annual Review of Medicine, vol. 64, pp. 393–406, 2013.
[4] S. M. Stahl, Stahl’s Essential Psychopharmacology: Neuroscientific Basis and Practical Applications, 4th ed. Cambridge, U.K.: Cambridge University Press, 2017.
[5] O. D. Howes and S. Kapur, “The dopamine hypothesis of schizophrenia: version III,” Schizophrenia Bulletin, vol. 35, no. 3, pp. 549–562, 2009.
[6] A. Abi-Dargham and M. Laruelle, “Mechanisms of action of second-generation antipsychotic drugs in schizophrenia: insights from brain imaging studies,” European Psychiatry, vol. 20, no. 1, pp. 15–27, 2005.
[7] R. R. Girgis, M. Slifstein, and A. Abi-Dargham, “The role of dopamine in schizophrenia,” Current Pharmaceutical Design, vol. 17, no. 2, pp. 153–165, 2011.
[8] K. Maeda et al., “Brexpiprazole I: In vitro and in vivo characterization of a novel serotonin–dopamine activity modulator,” Journal of Pharmacology and Experimental Therapeutics, vol. 350, no. 3, pp. 589–604, 2014.
[9] J. A. Lieberman, T. S. Stroup, and J. P. McEvoy, “Effectiveness of antipsychotic drugs in patients with chronic schizophrenia,” New England Journal of Medicine, vol. 353, no. 12, pp. 1209–1223, 2005.
[10] L. Farde, A. L. Nordström, F. A. Wiesel, S. Pauli, C. Halldin, and G. Sedvall, “Positron emission tomographic analysis of central D1 and D2 dopamine receptor occupancy in patients treated with classical neuroleptics and clozapine,” Archives of General Psychiatry, vol. 49, no. 7, pp. 538–544, 1992.
[11] N. C. Andreasen, “Symptoms, signs, and diagnosis of schizophrenia,” The Lancet, vol. 346, no. 8973, pp. 477–481, 1995.
[12] D. C. Goff and J. T. Coyle, “The emerging role of glutamate in the pathophysiology and treatment of schizophrenia,” American Journal of Psychiatry, vol. 158, no. 9, pp. 1367–1377, 2001.
[13] J. M. Kane and J. M. Correll, “Pharmacologic treatment of schizophrenia,” Dialogues in Clinical Neuroscience, vol. 12, no. 3, pp. 345–357, 2010.
[14] T. R. Insel, “Rethinking schizophrenia,” Nature, vol. 468, no. 7321, pp. 187–193, 2010.
[15] B. J. Sadock, V. A. Sadock, and P. Ruiz, Kaplan & Sadock’s Synopsis of Psychiatry, 11th ed. Philadelphia, PA, USA: Wolters Kluwer, 2015.
